Penicillin G Potassium Injection, Powder, For Solution
NDC Package 51662-1709-1

11-digit billing NDC: 51662170901

Package Information

Penicillin G Potassium injection is therapyPenicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1709 and is authorized under FDA application ANDA065448.

Identification & Billing

NDC Package Code
51662-1709-1
Package Description
1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL
Product Code
11-Digit Billing Format
51662170901
RxNorm Crosswalk
  • RxCUI: 863538 - penicillin G potassium 1,000,000 UNT/ML Injectable Solution
  • RxCUI: 863538 - penicillin G potassium 1000000 UNT/ML Injectable Solution
  • RxCUI: 863538 - Penicillin G K+ 1000000 UNT/ML Injectable Solution
  • RxCUI: 863538 - Penicillin G Pot 1000000 UNT/ML Injectable Solution
  • RxCUI: 863538 - penicillin G potassium 20,000,000 UNT per 11.5 ML Injectable Solution

Clinical Specifications

Proprietary Name
Penicillin G Potassium
Non-Proprietary Name
Penicillin G Potassium
Substance Name
Penicillin G Potassium
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Usage Information
TherapyPenicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G.Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued.To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Product Type
Human Prescription Drug
FDA Application #
ANDA065448
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-01-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1709-1 identifies a specific commercial package of 1 injection, powder, for solution in 1 vial of Penicillin G Potassium, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, powder, for solution is formulated for intramuscular; intravenous use and contains penicillin g potassium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on December 01, 2024. The current certification is valid through December 31, 2027.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662170901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1709-1
11-Digit CMS (5-4-2)
51662-1709-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.